Navidea biopharmaceuticals announces extension of subscription period to august 24, 2022 and updated terms of its previously announced rights offering

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today that it has extended the initial rights offering subscription period until 5:00 pm eastern time on wednesday, august 24, 2022 and has updated certain pricing information for its rights offering. each subscription right will entitle the holder to purchase one unit, at a
NAVB Ratings Summary
NAVB Quant Ranking